Human natural killer (NK) cells in circulation are categorised into two subsets. The majority (>95%) are CD56dimCD16+, characterised as highly cytolytic against infected target cells. A small proportion (<5%) are CD56brightCD16-/dim, which have decreased cytolytic capacity, but markedly increased production of cytokines such as Interferon-γ. We are investigating Herpes Simplex Virus (HSV) vaccine design using a Toll-like receptor 2 (TLR-2) stimulating lipid-conjugated HSV peptide, “Pam2Cys-30”. Previously, we observed that CD4 T lymphocyte responses to Pam2Cys-30 were enhanced by the presence of NK cells in coculture with dendritic cells (DC) and CD4 T lymphocytes. Furthermore, NK cells were directly activated by Pam2Cys-30 and could activate CD4 T lymphocytes in the absence of other antigen presenting cells. Therefore, we investigated Pam2Cys-30 activation of NK cells, to examine and compare responses between the NK cell subsets. When NK cells were stimulated by Pam2Cys-30 and cultured overnight, both CD56bright and CD56dimCD16+ NK cell subsets were activated as shown by CD69 expression, however, expression was higher in CD56dimCD16+ cells. After cell sorting, both subsets were activated independently of each other when stimulated by Pam2Cys-30. We also observed that in the CD56dimCD16+ population, stimulus by Pam2Cys-30 triggered a significant proportion of cells to downregulate CD16. This CD56dimCD16- population was highly activated as shown by high expression levels of CD69 and HLA-DR. Intracellular cytokine staining demonstrated that the CD56dimCD16- population had a higher percentage of IFN-γ+ cells than the other NK cell subsets. Determining the mechanism by which Pam2Cys-30 is taken up by NK cells and induces phenotypic and functional changes in each subset is ongoing work. Characterising how NK cells respond to Pam2Cys-30 is important for understanding their contribution to T cell activation and demonstrates the importance of considering NK cells in addition to DC when designing novel vaccine candidates.